THERIVA BIOLOGICS INC (TOVX)

US87164U4094 - Common Stock

0.37  0 (-0.19%)

Fundamental Rating

1

Taking everything into account, TOVX scores 1 out of 10 in our fundamental rating. TOVX was compared to 586 industry peers in the Biotechnology industry. TOVX has a bad profitability rating. Also its financial health evaluation is rather negative. TOVX has a expensive valuation and it also scores bad on growth.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TOVX has reported negative net income.
In the past year TOVX has reported a negative cash flow from operations.
TOVX had negative earnings in each of the past 5 years.
In the past 5 years TOVX always reported negative operating cash flow.

1.2 Ratios

TOVX has a Return On Assets of -33.23%. This is in the better half of the industry: TOVX outperforms 66.55% of its industry peers.
Looking at the Return On Equity, with a value of -46.22%, TOVX is in the better half of the industry, outperforming 68.78% of the companies in the same industry.
Industry RankSector Rank
ROA -33.23%
ROE -46.22%
ROIC N/A
ROA(3y)-31.35%
ROA(5y)-67.33%
ROE(3y)-39.46%
ROE(5y)-77.34%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

TOVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for TOVX has been increased compared to 1 year ago.
TOVX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TOVX is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -8.43, we must say that TOVX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TOVX (-8.43) is worse than 75.13% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that TOVX is not too dependend on debt financing.
TOVX has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.43
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

TOVX has a Current Ratio of 4.07. This indicates that TOVX is financially healthy and has no problem in meeting its short term obligations.
TOVX has a Current ratio of 4.07. This is comparable to the rest of the industry: TOVX outperforms 44.08% of its industry peers.
TOVX has a Quick Ratio of 4.07. This indicates that TOVX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.07, TOVX perfoms like the industry average, outperforming 45.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.07
Quick Ratio 4.07

More info and screens

1

3. Growth

3.1 Past

TOVX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.87%.
EPS 1Y (TTM)7.87%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 11.83% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y11.51%
EPS Next 2Y7.64%
EPS Next 3Y11.83%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TOVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TOVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.64%
EPS Next 3Y11.83%

More info and screens

0

5. Dividend

5.1 Amount

TOVX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERIVA BIOLOGICS INC

NYSEARCA:TOVX (5/20/2024, 12:22:34 PM)

0.37

0 (-0.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap6.35M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.23%
ROE -46.22%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.07
Quick Ratio 4.07
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)7.87%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y11.51%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y